Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2

February 27, 2026 updated by: Lindsay Bornheimer, University of Michigan

Feasibility, Acceptability, and Preliminary Effectiveness of a Cognitive Behavioral Suicide Prevention-focused Intervention Tailored to Adults Diagnosed With Schizophrenia Spectrum Disorders: Aim 2 RCT

Investigators will evaluate the feasibility and preliminary effectiveness of modified Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) in comparison to services-as-usual (SAU) in a randomized controlled trial. Investigators will recruit adult clients receiving services at a community mental health (CMH) setting who have a schizophrenia spectrum disorder and recent suicidal thoughts or behaviors within 3 months of screening (n=60). Client participants will be screened, enrolled and randomized to the CBSPp or SAU group. A 4-wave design will include quantitative assessments at baseline (T1), 1-month after baseline (T2), 3-months after baseline (T3), and 5-months after baseline (T4) with in-depth qualitative interviews at T3 for a random sample of adults in the CBSPp group (n=10). Providers (n=12) will be trained to deliver CBSPp and be assessed from T1-T3 to evaluate the implementation process, including in-depth qualitative interviews at T3.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

51

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Schizophrenia Spectrum Disorder
  • Suicide ideation and/or attempt within 3 months of screening
  • Ability to speak and read in English
  • 18 to 65 years of age

Exclusion Criteria:

  • Requiring emergency care (e.g. imminent plan to harm self) as determined by trained research staff administering the Columbia-Suicide Severity Rating Scale (C-SSRS)
  • Inappropriate for behavioral treatment according to own judgment in consultation with a treating clinician CMH
  • Impaired capacity (cognitive capacity)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cognitive Behavioral Suicide Prevention for psychosis (treatment group)
Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions in addition to standard/current services.
Cognitive and behavioral approach to suicide prevention tailored for individuals with psychosis
Active Comparator: Services as Usual (SAU; comparison group)
Services as usual involve standard and current services that clients are eligible for receiving.
Standard psychiatric and behavioral services provided at community mental health (e.g., case management, medication management)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Calgary Depression Rating Scale (CDRS)
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure depression, higher scores indicate greater depression (range of 0-27)
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
Positive and Negative Syndrome Scale (PANSS)
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure psychosis symptoms, higher scores indicate greater psychosis (range of 30-210)
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
Columbia Suicide Severity Rating Scale (C-SSRS)
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure suicide thoughts and behavior, higher scores indicate greater suicide thoughts and behavior (range of 0-5)
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Beck Hopelessness Scale
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure hopelessness, higher scores indicate greater hopelessness (range of 0-20)
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
Defeat Scale (D Scale)
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure defeat, higher scores indicate greater defeat (range of 0-64)
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
The Entrapment Scale
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure entrapment, higher scores indicate greater entrapment (range of 0-64)
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2022

Primary Completion (Actual)

May 1, 2025

Study Completion (Actual)

May 1, 2025

Study Registration Dates

First Submitted

April 12, 2022

First Submitted That Met QC Criteria

April 22, 2022

First Posted (Actual)

April 25, 2022

Study Record Updates

Last Update Posted (Actual)

March 20, 2026

Last Update Submitted That Met QC Criteria

February 27, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HUM00211008
  • R34MH123609 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Upload to NIMH Data Archive

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.